Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
Atzumi™ (dihydroergotamine(DHE)) nasal powder is the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults in an easy-to-use, easy-to-carry device.
Atzumi is the first and only product utilizing the SMART (Simple MucoAdhesive Release Technology) platform which combines a proprietary advanced powder and device technology to simplify delivery of DHE.
In clinical studies, Atzumi administration provided rapid and sustained DHE concentrations with low variability.
DURHAM, N.C., April 30, 2025 /PRNewswire/ — Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™(dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101.
Migraine is a neurological disorder that is thought to be the result of temporary changes in the chemicals, nerves and blood vessels in the brain, with symptoms that are often incapacitating. According to the American Migraine Foundation, approximately 40 million Americans live with migraine. It is the second leading cause of disability worldwide in terms of time lost to disability and most common cause of disability among young women.
'The approval of Atzumi is a milestone to celebrate, providing a new option for the acute treatment of migraine combining long-proven benefits of DHE with a patient-friendly and easy-to-use delivery system developed based on SNBL's novel intranasal drug delivery platform technology,' said Dr. Ryoichi Nagata, President and CEO of Satsuma. 'We believe that Atzumi will contribute to improving the quality of life of patients struggling for relief from these highly disabling problems.'
'DHE plays a unique clinical role in the acute treatment of migraine, providing patients long lasting effects and the unique ability to provide benefit even when taken late in a migraine attack. The convenience of Atzumi, the only DHE nasal powder, will offer patients ease of use combined with the important known DHE clinical advantages', said Dr. Stewart J. Tepper, M.D., Vice President of the New England Institute for Neurology and Headache in Stamford, Connecticut.
About Atzumi
Atzumi is a proprietary drug device product incorporating both Satsuma's advanced nasal powder formulation of dihydroergotamine (DHE) administered via its unique nasal delivery device. The product is designed to provide patients an easy-to-use and easy-to-carry treatment option.
The FDA approval for Atzumi is based on two clinical studies (Phase 1 PK trial and ASCEND Phase 3 open-label, long-term safety trial), which demonstrated fast absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels over time as well as safety and tolerability in subjects with migraine.
About Dihydroergotamine (DHE)
Since its approval in 1946, DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has significant advantages versus other anti-migraine treatments for many patients. However, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration and/or sub-optimal clinical performance, have limited the widespread use of DHE.
IMPORTANT SAFETY INFORMATION
WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of Atzumi with strong CYP3A4 inhibitors is contraindicated.
Indication
Atzumi is an ergotamine derivative indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use
Atzumi is not indicated for the preventive treatment of migraine or for the management of hemiplegic migraine or migraine with brainstem aura.
Contraindications
Atzumi is not recommended in patients with:
Concomitant use of strong CYP3A4 inhibitors
Ischemic heart disease or coronary artery vasospasm
Uncontrolled hypertension, peripheral arterial diseases, sepsis, following vascular surgery, or severe hepatic or renal impairment
Hypersensitivity to ergot alkaloids
Concomitant use of other 5-HT₁ agonists or ergotamine-containing or ergot-type medication within 24 hours
Concomitant use of peripheral and central vasoconstrictors
Warnings and Precautions
Atzumi may cause:
Cardiac events: Cardiac events in patients with risk factors of coronary artery diseases: Consider administration of the first dose of Atzumi under medical supervision (including the use of an electrocardiogram)
Cerebrovascular events: Cerebrovascular events (eg, cerebral hemorrhage, subarachnoid hemorrhage, and stroke) have been reported, particularly with dihydroergotamine mesylate injection
Vasospasm/elevated blood pressure: Dihydroergotamine may cause vasospasm or elevation in blood pressure
Medication overuse headache: Detoxification may be necessary
Preterm labor: Advise pregnant women of the risk
Fibrotic complications: Rare cases have been reported following prolonged daily use of dihydroergotamine mesylate. Administration of Atzumi should not exceed the dosing guidelines or be used for chronic daily administration
Local irritation: Local irritation has been reported following administration of Atzumi
Most Common Adverse Reactions
Most common adverse reactions (incidence >1%) were rhinitis, nausea, altered sense of taste, application site reaction, dizziness, vomiting, somnolence, pharyngitis, and diarrhea.
Use in Special Populations
Pregnancy: Available data from published literature indicate an increased risk of preterm delivery with Atzumi us during pregnancy.
Lactation: Patients should not breastfeed during treatment with Atzumi and for 3 days after the last dose.
Please see the Atzumi Full Prescribing Information, including Boxed Warning and Medication Guide.
The risk information provided here is not comprehensive. The FDA-approved product labeling can be found at www.satsumarx.com. You can also call 1-888-273-2480 for additional information.
About Satsuma Pharmaceuticals
Satsuma Pharmaceuticals Inc., a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), is a late-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. Since its inception in 2016, Satsuma has focused on combining great science, cutting-edge technology and proven drug therapies to create improved therapeutic products that address the significant unmet needs of patients. Satsuma's team has extensive experience successfully developing, manufacturing and commercializing pharmaceutical products within both large and small companies, and we have particular expertise in the area of drug-device combination products delivered via inhalation. For further information, please visit www.satsumarx.com.
About SNBL
Shin Nippon Biomedical Laboratories, Ltd. ('SNBL') (TSE:2395) is a listed nonclinical contract research organization (CRO) that was founded in Kagoshima, Japan, in 1957. Based on its corporate philosophy of 'Committed to the environment, life, and people', and with a proven track record of accomplishment as the oldest and most established Japanese nonclinical CRO, SNBL is proud to offer a comprehensive portfolio of services and solutions for drug discovery and development for pharmaceutical companies, biotech ventures, universities, and research institutions both in Japan and overseas. The SNBL's Translational Research business engages in drug discovery, with the focus on business development and out-licensing of its proprietary intranasal drug delivery technologies and intranasal devices. For further information, please visit https://en.snbl.com/.
Cautionary Note on Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Satsuma's future business, future position and results of operations, including estimates, forecasts, targets and plans for Satsuma. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could' 'anticipates', 'estimates', 'projects' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding SNBL's business, including uncertainty of commercial success for new and existing products; claims or concerns regarding the safety or efficacy of product candidates; general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; the impact of health crises such as the coronavirus pandemic on Satsuma and its clients and suppliers, including foreign governments in countries in which Satsuma operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Satsuma's operations and the timing of any such divestment(s); and other factors identified in SNBL's most recent securities report ('Yuka Shoken Houkokusho') and SNBL's other reports filed with the Financial Services Agency, available on SNBL's website at: https://en.snbl.com/ir/library or at https://disclosure.edinet-fsa.go.jp/. SNBL does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or related stock exchange rule. Past performance is not an indicator of future results and the results or statements of SNBL in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of SNBL's future results.
Medical Information
This press release contains information about product candidates that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
Inquiries: Satsuma Pharmaceuticals, Inc.E-mail: info@satsumarx.comWebsite: www.satsumarx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Your CBD Store and Small Business Owners Call on Governor Abbott to Veto SB 3, Citing Devastating Economic Consequences
Sunmed™ | Your CBD Store® urges Texas Governor Greg Abbott to Veto Senate Bill 3 AUSTIN, Texas, June 9, 2025 /PRNewswire/ — Sunmed™ | Your CBD Store®, along with its small business hemp retailers across the state, are urging Governor Greg Abbott to veto Senate Bill 3 (SB 3) in account of depriving law-abiding small businesses the opportunity to offer Texans wellness and therapeutic products that foster the Texas economy. Unless Governor Abbott issues a veto against it, SB 3 will ban most hemp-derived cannabinoid products currently sold at over 7,500 licensed retail establishments throughout Texas. Sunmed | Your CBD Stores are owned by independent small businesses that rely on the sale of legal and wellness hemp-derived cannabinoid products to make a living and support their families. Ralph Paul, who owns a Sunmed | Your CBD Store in Keller, Texas, warns: 'If SB 3 is signed into law, I'll have no choice but to shut down my businesses. This isn't just about product bans, it's about laying off employees, defaulting on leases, and losing everything we've built. We operate legally and transparently under the Texas Hemp Program. We don't deserve to be collateral damage in a political agenda.' Across the state, retailers are bracing for closures. Gary Brandt, owner of a Sunmed | Your CBD Store in Lakeway, Texas, adds: 'I've invested my savings, hired local staff, and served customers who depend on our wellness products. This bill doesn't just hurt businesses, it devastates families, communities, and the state's fiscal health. We're urging Governor Abbott to veto SB 3 and stand with small businesses.' According to the 2025 Economic Impact of Hemp Cannabinoid Processing and Manufacturing on Texas report by Whitney Economics, the hemp-derived cannabinoid industry is a cornerstone of the Texas economy: 53,300 Texans employed $2.1 billion in wages paid $5.5 billion in revenue generated $267 million in retail sales tax contributed $10–10.5 billion total economic impact The Whitney report underscores that this industry's influence extends beyond storefronts and into rural farming, supply chains, distribution, and manufacturing. Over 8,500 total licenses, spanning retail, wholesale, and manufacturing, will be rendered obsolete. Sunmed | Your CBD Store and its affiliate network support responsible regulation and consumer safety. However, SB 3 amounts to a prohibition and wipes out a thriving, tax-contributing industry that operates under a clear legal framework. Call to ActionWe urge all Texans to oppose SB 3. Contact Governor Abbott and request that he veto this harmful legislation: Call Governor Abbott: (512) 463-2000 Email the Governor: Contact Form Sign the Texas Hemp Business Council Petition: Sign Petition Sign the U.S. Hemp Roundtable Petition: Sign Petition Sunmed stands with small businesses and the Texas communities they serve. We believe in protecting consumer access to safe, effective hemp products and supporting the local entrepreneurs who provide them. Join us in defending our industry, our economy, and our right to choose. Contact Patrick ShatzerSunmed l Your CBD Storecustomersupport@ About Sunmed™ | Your CBD Store® Sunmed | Your CBD Store, an affiliate of Sunflora, Inc., is the largest hemp retailer in the United States and the exclusive home of award-winning, hemp-derived Sunmed products. With 260+ nationwide locations across 39 states, the brand offers a premium in-store customer experience with access to 150+ nonpharmaceutical wellness formulas, including clinically proven sleep gummies, pain relief topicals, USDA-organic oil tinctures, and CBD for pets. Through in-store education, community involvement, and groundbreaking clinical research, Sunmed strives to empower modern wellness and enhance people's lives with natural science-backed products. Learn more at
Malaysian Reserve
8 hours ago
- Malaysian Reserve
123Invent Inventor Develops Improved Bra for Curvier Women
PITTSBURGH, June 9, 2025 /PRNewswire/ — 'As a curvier woman, I hated the discomfort associated with wearing a traditional bra. I wanted to create a more comfortable option for me, my daughter, and other women with curves,' said an inventor, from Wagga, NSW, Australia, 'so I invented the CroBra (by Char). My design provides added comfort and support, and the improved sizing guide helps you select the right size.' The patent-pending invention provides an improved bra option for curvier women. In doing so, it prevents the bra from riding up and digging into the skin. It also helps prevent bulging. As a result, it increases comfort and support. Additionally, the invention features a unique design that is easy to wear. The CroBra (by Char) is currently available for licensing or sale to manufacturers or marketers. For more information, visit Or contact Lidia Ilievski at 045-720-0678 or email info@
Malaysian Reserve
12 hours ago
- Malaysian Reserve
Health-E Commerce® expands telehealth offerings with LifeMD™ to provide sleep treatments via FSA Store® and HSA Store®
New collaboration delivers 50% off prescription sleep support for new customers who are struggling with insomnia and sleep disruption DALLAS, June 9, 2025 /PRNewswire/ — Health-E Commerce, the parent brand of FSA Store and HSA Store, the first and leading online stores dedicated to selling only FSA- and HSA-eligible products and services, announced today that it has expanded its telehealth collaboration with LifeMD™, a leader in virtual care. This latest initiative gives FSA and HSA users affordable, convenient access to FDA-approved prescription sleep treatments at a time when better sleep care is urgently needed. According to the CDC, insufficient sleep is linked to higher risks of obesity, diabetes, heart disease, and depression, which means expanded access to treatment is not just beneficial, it's essential. The arrangement allows new customers who shop at FSA Store or HSA Store to receive 50% off prescription sleep medications from LifeMD, with no in-person appointments required. Following a free virtual consultation, approved patients can have non-addictive, physician-prescribed treatments discreetly delivered to their door, making it easier than ever to address sleep concerns with clinically backed solutions. 'The connection between sleep and our overall physical and mental health is undeniable, and poor sleep can even impact our productivity at work and our overall quality of life,' said Keri Kaiser, chief revenue officer for Health-E Commerce. 'The expansion of our telehealth collaboration with LifeMD gives consumers more options for diagnosing and treating sleep disorders and improving sleep health, while saving money by using tax-free FSA- and HSA-eligible services. We're proud to simplify access to care for millions of Americans and to maximize their healthcare dollars.' Many individuals who experience poor sleep rely on over-the-counter remedies that may not be effective for persistent insomnia or sleep disruptions. Fortunately, LifeMD's prescription sleep solutions are designed to address the root causes of poor sleep with medications that target sleep onset, duration, and quality, including Ramelteon, Doxepin, and Trazodone. Eligibility for prescription treatments is determined by a licensed LifeMD physician and backed by LifeMD's 4.9-star patient satisfaction rating. 'We're proud to expand our telehealth collaboration with Health-E Commerce to give individuals and families who are enrolled in FSAs and HSAs access to clinical support to improve sleep health and their overall quality of life,' said Nicholas Alvarez, co-founder and chief acquisition & growth officer at LifeMD. 'Everyone deserves access to quality medical care that is convenient and affordable, and by collaborating with FSA Store and HSA Store, we are able to effectively extend the reach of our services to individuals and families across the country.' LifeMD's sleep solutions are now available at and alongside other telehealth services for home sleep apnea testing, CPAP devices and supplies, CPAP alternatives, and more. This launch reinforces Health-E Commerce's mission to make tax-free healthcare dollars work harder for the more than 70 million Americans enrolled in pre-tax health accounts. To learn more or access eligible sleep health services and products, visit or About Health-E CommerceHealth-E Commerce is the parent brand to FSA Store and HSA Store, online stores that serve the 70+ million consumers enrolled in pre-tax health and wellness accounts. The company also created Caring Mill®, a popular private-label line of health products through which a portion of every purchase is donated to the Children's Health Fund. Since 2010, the Health-E Commerce brands have led the direct-to-consumer e-commerce market for exclusively pre-tax health and wellness benefits. Health-E Commerce plays an essential role in expanding eligibility for important new product and telehealth categories within the list of eligible medical expenses. About LifeMDLifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit
